The CROWN trial presented at the 2024 American Society of Clinical Oncology meeting showed that lorlatinib, a third-generation ALK inhibitor from Pfizer, provided the longest progression-free survival (PFS) reported for any targeted therapy in advanced non-small cell lung cancer (NSCLC). The benefits included a 72% improvement in PFS and a 92% reduction in intracranial progression compared to crizotinib. The study included patients with ALK-positive NSCLC who had received no prior systemic treatment for metastatic disease. While some experts questioned the use of crizotinib as a comparator, the results showed that lorlatinib significantly improved outcomes for patients with ALK-positive NSCLC.
Source link
‘Outstanding’ 5 Year PFS With Lorlatinib in ALK+ NSCLC
